August 23, 2017 12:43 AM ET

Biotechnology

Company Overview of Galena Biopharma, Inc.

Company Overview

Galena Biopharma, Inc., a biopharmaceutical company, develops hematology and oncology therapeutics that address unmet medical needs. The company develops GALE-401 (anagrelide controlled release), which completed Phase II clinical trial for the treatment of patients with myeloproliferative neoplasms to lower elevated platelet levels. It also develops NeuVax (nelipepimut-S), which is in Phase IIb clinical trial in combination with trastuzumab for HER2 1+ and 2+ node positive and high-risk node negative breast cancer patients; Phase II clinical trial in combination with trastuzumab for HER2 3+ breast cancer patients; Phase II clinical trial for women with ductal carcinoma in situ of the breast;...

2000 Crow Canyon Place

Suite 380

San Ramon, CA 94583

United States

Founded in 2003

14 Employees

Phone:

855-855-4253

Fax:

925-498-7799

Key Executives for Galena Biopharma, Inc.

Interim Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer
Age: 55
Total Annual Compensation: $128.3K
Chief Medical Officer and Executive Vice President
Age: 55
Total Annual Compensation: $540.0K
Interim General Counsel and Corporate Secretary
Age: 64
Total Annual Compensation: $425.1K
Vice President of Finance and Corporate Controller
Age: 32
Total Annual Compensation: $234.1K
Compensation as of Fiscal Year 2016.

Galena Biopharma, Inc. Key Developments

Galena Biopharma, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017

Galena Biopharma, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2017. For the quarter, the company reported operating loss of $4,911,000, loss from continuing operations of $7,102,000, loss from discontinued operations of $1,302,000, net loss of $8,404,000, compared to operating loss of $9,292,000, income from continuing operations of $8,278,000, loss from discontinued operations of $2,889,000, net income of $5,389,000, for the same period a year ago. Diluted net loss per share, continuing operations was $0.19 against diluted net income per share, continuing operations of $0.90 a year ago. Diluted net loss per share was $0.22 against diluted net income per share of $0.58 a year ago. For the year to date, the company reported, operating loss of $9,999,000, loss from continuing operations of $9,384,000, loss from discontinued operations of $10,738,000, net loss of $20,122,000, compared to operating loss of $18,260,000, loss from continuing operations of $4,824,000, loss from discontinued operations of $6,280,000, net loss of $11,104,000, for the same period a year ago. Diluted net loss per share, continuing operations was 0.29 against $0.13 a year ago. Diluted net loss per share was $0.63 against $0.30 a year ago.

Galena Biopharma, Inc. announced delayed 10-Q filing

On 08/09/2017, Galena Biopharma, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Galena Biopharma, Inc., SELLAS Life Sciences Group AG - M&A Call

To discuss the merger agreement between the Galena Biopharma, Inc and SELLAS Life Sciences Group Ltd

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
August 8, 2017
--
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Galena Biopharma, Inc., please visit www.galenabiopharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.